NCT05798156 2026-04-08
R-Pola-Glo
Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest
Phase 2 Active not recruiting
Clinical Trials
15 trialsNCT07502872 2026-03-31
TPG
Brown University
Phase 2 Not yet recruiting
NCT07480850 2026-03-18
Efficacy and Safety of Glofitamab Combined With GemOxin the Treatment of Refractory Diffuse Large B-Cell Lymphoma
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Phase 2 Active not recruiting
NCT06765317 2025-11-26
A Study of Glofitamab-based Treatment in People With Diffuse Large B-cell Lymphoma
Memorial Sloan Kettering Cancer Center
Phase 2 Recruiting
NCT02992522 2025-09-09
Obinutuzumab, Venetoclax, and Lenalidomide in Treating Patients With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma
Ohio State University Comprehensive Cancer Center
Phase 1 Active not recruiting
NCT02393157 2025-08-08
O-ICE
New York Medical College
Phase 2 Recruiting
NCT03401853 2025-07-22
Pembrolizumab With Rituximab or Obinutuzumab in Treating Patients With Relapsed or Refractory Follicular Lymphoma or Diffuse Large B Cell Lymphoma
University of Washington
Phase 2 Terminated
NCT06867536 2025-03-18
GLOHRT-01
Huazhong University of Science and Technology
Phase 2 Not yet recruiting
NCT06656234 2024-10-24
The Effectiveness and Safety of Glofitamab in Real-World Clinical Practice Among Chinese Adult Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma: A Prospective, Observational, Multicenter Study
Ruijin Hospital
Not yet recruiting
NCT02529852 2024-09-19
A Phase I/II Study of Lenalidomide and Obinutuzumab With CHOP for Diffuse Large B Cell Lymphoma
M.D. Anderson Cancer Center
Phase 1/2 Completed
NCT05823701 2023-04-21
Chidamide, Azacitidine Combined With GM Regimen for Relapsed and Refractory DLBCL Patients
The First Affiliated Hospital of Soochow University
Phase 2 Unknown
NCT03276468 2023-01-10
Evaluation of Atezolizumab-Venetoclax-Obinutuzumab Combination in Relapse/Refractory Lymphomas
The Lymphoma Academic Research Organisation
Phase 2 Completed
NCT02499003 2022-03-31
GOAL: GA101 Plus Pixantrone for Relapsed Aggressive Lymphoma
Johannes Gutenberg University Mainz
Phase 2 Completed
NCT02987400 2022-02-16
Combination of Obinutuzumab and Venetoclax in Relapsed or Refractory DLBCL
Arbeitsgemeinschaft medikamentoese Tumortherapie
Phase 2 Completed
NCT02420210 2018-06-06
Bendamustine, Obinutuzumab, and Dexamethasone in Older Patients With Diffuse Large B-cell Lymphoma
University of Chicago
Phase 2 Terminated